Development of Salamanca uranium project on track


Published 15-MAR-2017 14:56 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

In releasing its half yearly report on Wednesday, Berkeley Energia (ASX:BKY LSE:BKY ) informed the market that preparations for the Salamanca uranium project located in Spain were on track with the group having completed major land acquisitions ahead of mine development, ordered the main equipment for the crushing circuit and engaged an engineering firm to undertake the Front End Engineering and Design (FEED) works.

Some of the highlights of the last six months have included the release of the Definitive Feasibility Study (DFS), which confirmed Salamanca as one of the world’s lowest cost uranium producers, as well as the negotiation of an offtake agreement with Interalloys.

The oversubscribed US$30 million capital raising attracted high profile London based institutional investors, leaving the company funded through to the construction phase while also providing working capital.

Further promising news emerged last week with the ASX announcing that BKY would be included in the All Ordinaries index effective from March 20, an important development in terms of attracting stronger interest from institutional investors.

Despite the planets aligning for BKY, its share price has retraced from a high of $1.20 in late January to trade in the vicinity of 90 cents. This could perhaps represent a buying opportunity given it arguably relates to a normal drop-off in newsflow over the Christmas period and in the lead up to the commencement of construction.

The fact remains that the same dynamics which underpinned a 50% share price increase between mid-December and late January remain relevant. A number of brokers cover the stock and the consensus 12 month price target is $1.30, perhaps supporting the fact that a resumption of news flow in 2017 will provide share price momentum.

However, it should be noted that broker projections and price targets are only estimates and may not be met. Also, historical data in terms of earnings performance and/or share trading patterns should not be used as the basis for an investment as they may or may not be replicated. Those considering this stock should seek independent financial advice.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free